These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 19604267)
1. Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Ortiz RH; Leon DA; Estevez HO; Martin A; Herrera JL; Romo LF; Portaels F; Pando RH Clin Exp Immunol; 2009 Aug; 157(2):271-81. PubMed ID: 19604267 [TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Mve-Obiang A; Lee RE; Portaels F; Small PL Infect Immun; 2003 Feb; 71(2):774-83. PubMed ID: 12540557 [TBL] [Abstract][Full Text] [Related]
3. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Torrado E; Adusumilli S; Fraga AG; Small PL; Castro AG; Pedrosa J Infect Immun; 2007 Aug; 75(8):3979-88. PubMed ID: 17517872 [TBL] [Abstract][Full Text] [Related]
8. The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer. Hall BS; Hsieh LT; Sacre S; Simmonds RE Front Immunol; 2021; 12():788146. PubMed ID: 35154073 [TBL] [Abstract][Full Text] [Related]
9. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. George KM; Chatterjee D; Gunawardana G; Welty D; Hayman J; Lee R; Small PL Science; 1999 Feb; 283(5403):854-7. PubMed ID: 9933171 [TBL] [Abstract][Full Text] [Related]
10. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions. Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095 [TBL] [Abstract][Full Text] [Related]
11. Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. Martins TG; Gama JB; Fraga AG; Saraiva M; Silva MT; Castro AG; Pedrosa J PLoS One; 2012; 7(2):e32740. PubMed ID: 22393444 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer. Bolz M; Bénard A; Dreyer AM; Kerber S; Vettiger A; Oehlmann W; Singh M; Duthie MS; Pluschke G PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004431. PubMed ID: 26849213 [TBL] [Abstract][Full Text] [Related]
13. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Adusumilli S; Mve-Obiang A; Sparer T; Meyers W; Hayman J; Small PL Cell Microbiol; 2005 Sep; 7(9):1295-304. PubMed ID: 16098217 [TBL] [Abstract][Full Text] [Related]
14. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. Hong H; Coutanceau E; Leclerc M; Caleechurn L; Leadlay PF; Demangel C PLoS Negl Trop Dis; 2008; 2(10):e325. PubMed ID: 18941518 [TBL] [Abstract][Full Text] [Related]
15. Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Fraga AG; Cruz A; Martins TG; Torrado E; Saraiva M; Pereira DR; Meyers WM; Portaels F; Silva MT; Castro AG; Pedrosa J Infect Immun; 2011 Jan; 79(1):421-30. PubMed ID: 20974825 [TBL] [Abstract][Full Text] [Related]
17. Induced Synthesis of Mycolactone Restores the Pathogenesis of Strong E; Hart B; Wang J; Orozco MG; Lee S Front Immunol; 2022; 13():750643. PubMed ID: 35401531 [No Abstract] [Full Text] [Related]